262 related articles for article (PubMed ID: 15007879)
1. [In vitro activity of a new semisynthetic echinocandin, micafungin, against clinical isolates of Candida species isolated in Tenri Hospital].
Komatsu M; Aihara M; Shimakawa K; Iwasaki M; Nagasaka Y; Fukuda S; Abe N; Matsuo S
Jpn J Antibiot; 2003 Dec; 56(6):705-11. PubMed ID: 15007879
[TBL] [Abstract][Full Text] [Related]
2. [Antifungal susceptibility among the isolates of yeast from the University Hospital of the Ryukyus].
Ohta C; Yamane N; Nakasone I; Onaga S; Nakamura K
Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi; 2005; 16(2):127-33. PubMed ID: 16536058
[TBL] [Abstract][Full Text] [Related]
3. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
4. Antifungal susceptibility of Candida isolates at one institution.
Katsuragi S; Sata M; Kobayashi Y; Miyoshi T; Yamashita Y; Neki R; Horiuchi C; Yamanaka K; Kamiya C; Iwanaga N; Tanaka H; Ikeda T; Yoshimatsu J
Med Mycol J; 2014; 55(1):E1-7. PubMed ID: 24682093
[TBL] [Abstract][Full Text] [Related]
5. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
[TBL] [Abstract][Full Text] [Related]
6. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
7. Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts.
Park BJ; Park JC; Taguchi H; Fukushima K; Hyon SH; Takatori K
Biochem Biophys Res Commun; 2006 Aug; 347(2):401-5. PubMed ID: 16831406
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital.
Arikan S; Sancak B; Hascelik G
Med Mycol; 2005 Mar; 43(2):171-8. PubMed ID: 15832560
[TBL] [Abstract][Full Text] [Related]
9. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
Marco F; Pfaller MA; Messer SA; Jones RN
Diagn Microbiol Infect Dis; 1998 Sep; 32(1):33-7. PubMed ID: 9791755
[TBL] [Abstract][Full Text] [Related]
10. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.
Uchida K; Nishiyama Y; Yokota N; Yamaguchi H
J Antibiot (Tokyo); 2000 Oct; 53(10):1175-81. PubMed ID: 11132964
[TBL] [Abstract][Full Text] [Related]
11. In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species.
Nishi I; Sunada A; Toyokawa M; Asari S; Iwatani Y
J Infect Chemother; 2009 Feb; 15(1):1-5. PubMed ID: 19280292
[TBL] [Abstract][Full Text] [Related]
12. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis.
Melkusová S; Bujdáková H; Volleková A; Myoken Y; Mikami Y
Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole.
Martín E; Parras P; Lozano MC
Chemotherapy; 1992; 38(5):335-9. PubMed ID: 1337508
[TBL] [Abstract][Full Text] [Related]
14. [Susceptibility of yeasts to antifungal agents in Kaunas University of Medicine Hospital].
Skrodeniene E; Dambrauskiene A; Vitkauskiene A
Medicina (Kaunas); 2006; 42(4):294-9. PubMed ID: 16687901
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.
Cuenca-Estrella M; Mellado E; Díaz-Guerra TM; Monzón A; Rodríguez-Tudela JL
J Antimicrob Chemother; 2000 Sep; 46(3):475-7. PubMed ID: 10980178
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
Pfaller MA; Messer SA; Gee S; Joly S; Pujol C; Sullivan DJ; Coleman DC; Soll DR
J Clin Microbiol; 1999 Mar; 37(3):870-2. PubMed ID: 9986880
[TBL] [Abstract][Full Text] [Related]
17. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
[TBL] [Abstract][Full Text] [Related]
18. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide.
Mikamo H; Sato Y; Tamaya T
J Antimicrob Chemother; 2000 Sep; 46(3):485-7. PubMed ID: 10980180
[TBL] [Abstract][Full Text] [Related]
19. [Molecular epidemiology and antifungal susceptibility of Candida species isolated from urine samples of patients in intensive care unit].
Yüksekkaya S; Fındık D; Arslan U
Mikrobiyol Bul; 2011 Jan; 45(1):137-49. PubMed ID: 21341168
[TBL] [Abstract][Full Text] [Related]
20. [The in vitro antifungal activities of fluconazole against pathogenic yeasts recently isolated from clinical specimens].
Yamaguchi H; Igari J; Kume H; Abe M; Oguri T; Kanno H; Kawakami S; Okuzumi K; Fukayama M; Ito A; Kawata K; Uchida K
Jpn J Antibiot; 1997 Sep; 50(9):799-805. PubMed ID: 9394240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
